|
|
Article: Safety concerns raised about weight loss drug. (Manufacturer says Charges are 'Incorrect').
- Article from:
- OB GYN News
- Article date:
- May 15, 2002
- Author:
CopyrightCOPYRIGHT 2002 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Food and Drug Administration is collecting and analyzing data on sibutramine as the agency prepares to respond to a citizen's petition calling for the weight loss drug's withdrawal from the market.
In March, the public advocacy group Public Citizen filed a citizen's petition with the FDA, stating that the drug had been associated with 29 deaths and "hundreds of serious adverse reactions" since its introduction in 1998. In the petition, the group said that the drug has only a "meager" effect and should be withdrawn from the market "immediately"
Sibutramine, a serotonin-norepinephrime reuptake inhibitor marketed as Meridia by Abbott Laboratories, was ...